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Evaluation of Vancomycin Dosing and Corresponding Drug Concentrations in
Neonatal Intensive Care Unit (NICU) Patients
Christine Lam, PharmD, and Jenny Boucher, BS, PharmD, JD, BCPS
Lehigh Valley Health Network, Allentown, Pennsylvania

Purpose:
The primary objective of this study is to retrospectively review the
relationship between vancomycin dosing strategy, age and attained
vancomycin trough concentrations.

Background:
•	Vancomycin is the drug of choice for empirical treatment of late-onset
1,2
septicemia in preterm infants
3,4,5
•	Many barriers to develop an optimal dosing regimen in neonates
– High interpatient and intrapatient variablility in vancomycin
pharmacokinetics

•	Expert consensus guidelines recommend for more aggressive dosing
and higher trough concentrations of vancomycin for the treatment of
6,7
methicillin-resistant Staphylococcus aureus (MRSA) infections
– Guidelines do not include neonatal population
– Lack of guidance on utilization of trough goals of 15-20 mcg/ml in the
neonate

Study Design:
•	Retrospective chart review
•	Inclusion Criteria:
– All neonatal patients [age 0 to 46 weeks post-menstrual age (PMA)]  
– Received intravenous (IV) treatment with vancomycin July 1, 2008
to June 30, 2013
– Had at least one trough concentration that was obtained 0-90
minutes before a dose at steady state  

•	Exclusion Criteria:
– Received IV treatment with vancomycin prior to June 30, 2008  
– No trough concentration reported during treatment.
– Age greater than 46 weeks PMA

•	The primary outcomes of the study:
– Number of patients achieving a target trough concentration of 5-15
mcg/ml in each dosing group and age group
– Average vancomycin dose necessary to achieve the target trough in
each age group

•	Lack of consensus for optimal dosing of vancomycin in preterm and full
term neonates

Methods:
• Stratify patients into predetermined categories:
– Vancomycin dosing and age range

•	Assess relationship between categories
•	Evaluate attainment of vancomycin concentrations within each category
•	Patient-specific information to be collected will include:
– Age [PMA and Postnatal age (PNA)]
– Weight
– Vancomycin dose and frequency
– Days of vancomycin therapy
– Measured vancomycin trough concentrations
– Timing of vancomycin trough concentrations
– Location of infection and organism
– Documentation of organism eradication via cultures or clinical
determination by the neonatologist
– Daily serum creatinine from drug initiation to discontinuation
– Presence of any co-administered nephrotoxic drugs  
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